| scholarly article | Q13442814 |
| P50 | author | Seyedmojtaba Seyedmousavi | Q40062294 |
| Johan Mouton | Q42711138 | ||
| Willem Melchers | Q56859383 | ||
| Paul E. Verweij | Q70514014 | ||
| P2093 | author name string | Roger J M Brüggemann | |
| P2860 | cites work | Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis | Q28217179 |
| Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America | Q28263689 | ||
| Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism | Q30853962 | ||
| Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. | Q33613758 | ||
| In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species | Q33876423 | ||
| Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity | Q34228214 | ||
| Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis | Q34290034 | ||
| Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy | Q34754956 | ||
| Aspergillosis. Pathogenesis, clinical manifestations, and therapy | Q35038459 | ||
| Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis | Q35127833 | ||
| Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan | Q35666518 | ||
| Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007-2009. | Q35848799 | ||
| Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin | Q37190801 | ||
| Azole-resistance in Aspergillus: proposed nomenclature and breakpoints | Q37625111 | ||
| Use of Antifungal Combination Therapy: Agents, Order, and Timing | Q37767359 | ||
| Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR. | Q37926156 | ||
| Azole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene | Q38283306 | ||
| Therapeutic outcome in invasive aspergillosis | Q38970340 | ||
| Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure | Q42555868 | ||
| Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery. | Q44318186 | ||
| Combination therapy for invasive aspergillosis | Q45096996 | ||
| Azole-resistant central nervous system aspergillosis. | Q46094844 | ||
| Current role of echinocandins in the management of invasive aspergillosis. | Q53217028 | ||
| Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. | Q54342323 | ||
| Multi-azole resistance in Aspergillus fumigatus | Q56837308 | ||
| Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis | Q56993324 | ||
| Multiple-Triazole–Resistant Aspergillosis | Q63914862 | ||
| Invasive aspergillosis in critically ill patients without malignancy | Q80269940 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Aspergillus fumigatus | Q134359 |
| aspergillosis | Q259626 | ||
| pharmacodynamics | Q725307 | ||
| 14-alpha sterol demethylase | Q61546270 | ||
| murine model | Q122890741 | ||
| P304 | page(s) | 303-308 | |
| P577 | publication date | 2012-10-31 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis | |
| P478 | volume | 57 |
| Q49792124 | A new marker of echinocandins activity in an in vitro PK/PD model correlates with an animal model of Aspergillus fumigatus infection |
| Q40045642 | Animal Models for Studying Triazole Resistance in Aspergillus fumigatus. |
| Q35758334 | Aspergillus and aspergilloses in wild and domestic animals: a global health concern with parallels to human disease. |
| Q41441699 | Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. |
| Q42638073 | Effects of Echinocandins in Combination with Nikkomycin Z against Invasive Candida albicans Bloodstream Isolates and the fks Mutants |
| Q36757621 | Pharmacodynamics and dose-response relationships of liposomal amphotericin B against different azole-resistant Aspergillus fumigatus isolates in a murine model of disseminated aspergillosis |
| Q38919690 | Pharmacodynamics for antifungal drug development: an approach for acceleration, risk minimization and demonstration of causality. |
| Q37538782 | Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis |
| Q35385554 | Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model |
| Q34020402 | Population pharmacokinetic-pharmacodynamic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis |
| Q35076830 | Posaconazole prophylaxis in experimental azole-resistant invasive pulmonary aspergillosis. |
| Q48149197 | Triazole Resistance in Aspergillus spp.: A Worldwide Problem? |
Search more.